EMEA-002338-PIP01-18

Key facts

Active substance
Ianalumab
Therapeutic area
Gastroentology-Hepatology
Decision number
P/0041/2019
PIP number
EMEA-002338-PIP01-18
Pharmaceutical form(s)
Condition(s) / indication(s)
Treatment of autoimmune hepatitis
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Novartis Europharm Limited

E-mail: paediatric.enquiries@novartis.com
Tel. +41 6132 41111

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating